Bupropion/zonisamide
Bupropion/zonisamide (former tentative brand name Empatic, Excalia) is an experimental combination of bupropion which was under development for the treatment of obesity.[1][2][3] Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor.[1] The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.[1][4][5]
Combination of | |
---|---|
Bupropion | Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist |
Zonisamide | Sulfonamide anticonvulsant |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
(verify) |
See also
References
- "Bupropion/Zonisamide - AdisInsight".
- Empatic Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half
- Empatic Obesity Drug Information and News
- Ioannides-Demos LL, Piccenna L, McNeil JJ (2011). "Pharmacotherapies for obesity: past, current, and future therapies" (PDF). Journal of Obesity. 2011: 179674. doi:10.1155/2011/179674. PMC 3006492. PMID 21197148.
- Adan RA (February 2013). "Mechanisms underlying current and future anti-obesity drugs". Trends in Neurosciences. 36 (2): 133–40. doi:10.1016/j.tins.2012.12.001. PMID 23312373. S2CID 21974224.
DAT (DRIs) |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NET (NRIs) |
| ||||||||||||||
SERT (SRIs) |
| ||||||||||||||
VMATs |
| ||||||||||||||
Others |
| ||||||||||||||
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins |
Nicotinic acetylcholine receptor modulators | |||||
---|---|---|---|---|---|
nAChRs |
| ||||
Precursors (and prodrugs) |
| ||||
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.